| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00409-0201-10 | 00409-0201 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 17, 2011 | In Use | |
| 44087-4000-04 | 44087-4000 | Cladribine | Mavenclad | 10.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | Apr 1, 2019 | In Use | |
| 68788-8763-02 | 68788-8763 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 11, 2024 | In Use | |
| 70518-1398-03 | 70518-1398 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Nov 15, 2018 | In Use | |
| 68001-0488-07 | 68001-0488 | CAPECITABINE | CAPECITABINE | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb 22, 2021 | In Use | |
| 70954-0056-20 | 70954-0056 | Prednisone | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 6, 2021 | In Use | |
| 80425-0072-03 | 80425-0072 | Ondansetron 4mg, Ondansetron HCL | Ondansetron HCL | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 70771-1522-07 | 70771-1522 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 25021-0245-01 | 25021-0245 | Docetaxel Anhydrous | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 15, 2017 | In Use | |
| 00003-2291-11 | 00003-2291 | Elotuzumab | Empliciti | 300.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov 30, 2015 | In Use | |
| 00115-7037-01 | 00115-7037 | Methyltestosterone | Methitest | 10.0 mg/1 | Hormonal Therapy | Androgen | Oral | Oct 17, 1974 | In Use | ||
| 00172-7313-20 | 00172-7313 | Cyclosporine | Cyclosporine | 100.0 mg/mL | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Mar 29, 2005 | In Use | |
| 63187-0066-09 | 63187-0066 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 1, 2014 | In Use | |
| 63323-0145-07 | 63323-0145 | Floxuridine | Floxuridine | 500.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intra-arterial | Mar 15, 2001 | In Use | |
| 70518-3600-02 | 70518-3600 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 28, 2023 | In Use | |
| 64380-0949-01 | 64380-0949 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 24, 2022 | In Use | |
| 63187-0300-18 | 63187-0300 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 1, 2017 | In Use | |
| 43063-0746-12 | 43063-0746 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 17, 2017 | In Use | |
| 70518-1551-00 | 70518-1551 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 23, 2018 | In Use | |
| 70534-0001-00 | 70534-0001 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 27, 2022 | In Use | |
| 82293-0017-10 | 82293-0017 | Sunitinib Malate | Sunitinib Malate | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | May 1, 2024 | In Use | |
| 54868-5980-00 | 54868-5980 | Temozolomide | Temodar | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 26, 2009 | In Use | |
| 68788-8166-02 | 68788-8166 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 8, 2022 | In Use | |
| 69639-0106-01 | 69639-0106 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/20mL, 0.28 mg/20mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist, Substance P/Neurokinin 1 | Intravenous | Aug 1, 2023 | In Use | |
| 00143-9771-06 | 00143-9771 | Ondansetron Hydrochloride and Dextrose | Ondansetron Hydrochloride and Dextrose | 32.0 mg/50mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Aug 4, 2009 | In Use |
Found 11888 results — Export these results
Home